KPTI JPM HC Conference 2023 Karyopharm.pdf

1、12023 KARYOPHARM THERAPEUTICS INC.JP MORGAN 2023 HEALTHCARE CONFERENCE January 11,2023A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies22023 KARYOPHARM THERAPEUTICS INC.Richard PaulsonChief Executive OfficerOVERVIEW32023 KARYOPHARM THERAPEUTICS INC.Forward-looking Statement

2、s and Other Important InformationThis presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.Such forward-looking statements include those regarding Karyopharms preliminary fourthquarter and full year 2022 financial results;Karyoph

3、arms expected cash runway;the ability of selinexor or eltanexor to treat patients with multiple myeloma,endometrial cancer,myelofibrosis,myelodysplastic neoplasms,diffuse large B-cell lymphoma,and other diseases;expectations related to future clinical development and potential regulatory submissions

4、 of selinexor or eltanexor;expectations with respect to commercialization efforts;submissions to,and the review and potential approval of selinexor,eltanexor or any of its other product candidates by,regulatory authorities,including the Companys regulatory strategy,the anticipated availability of da

5、tato support such submissions,timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways;the expected design of the Companys clinical trials;and thetherapeutic potential of and potential clinical development plans for Karyopharms

6、product candidates,especially selinexor and eltanexor.Such statements are subject to numerous important factors,risks anduncertainties,many of which are beyond Karyopharms control,that may cause actual events or results to differ materially from Karyopharms current expectations.For example,there can